VK2735-101 oral part C
43 evidence topics · 7 sources
Objective
Oral formulation: safety and tolerability of a once-daily tablet for 28 days
Oral formulation: objectives stated in the poster
Oral formulation: Part C in the ClinicalTrials.gov record
Location and study date
Results through 40 mg in March 2024 and through 100 mg at ObesityWeek 2024
Study dates and site in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Primary completion (actual) | “2024-11-04” |
| Study completion (actual) | “2024-12-03” |
| Site city | “Adelaide” |
Study design
Oral formulation: extension of the subcutaneous phase 1 study
Oral formulation: dose escalation after review of each cohort
Oral formulation: dose escalation continued beyond 40 mg after the interim results
Oral formulation: exploratory daily to every-other-day cohort
Eligibility criteria
Oral formulation: healthy adults with a body mass index of at least 30 kg/m2
Inclusion and exclusion criteria in the ClinicalTrials.gov record (Parts A, B, and C)
Age range in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Minimum age | “18 Years” |
| Maximum age | “65 Years” |
Treatment
Oral formulation: daily and every-other-day regimens at 80 mg
Oral formulation: arms in the ClinicalTrials.gov record
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Oral formulation: safety and tolerability as the primary objective
Registered primary outcome measure (Parts A, B, and C)
Oral formulation: exploratory proportion with at least 5% weight loss
Statistical analysis description
Number of participants (Planned and analyzed)
Oral formulation: participants analyzed by cohort
Actual enrollment in the ClinicalTrials.gov record (Parts A, B, and C)
| Field | Registry value |
|---|---|
| Enrollment (actual) | “92” |
Description of analysis sets
Oral formulation: efficacy and safety populations
Oral formulation: mixed model for repeated measures
Oral formulation: tests for weight change and responder proportions
Results
Participant disposition
Oral formulation: early study discontinuation by cohort
Baseline characteristics
Oral formulation: mean baseline characteristics by cohort
| Group | Age | Sex, M:F (%) | White (%) | Weight (kg) | BMI (kg/m2) |
|---|---|---|---|---|---|
| Placebo (n=19) | “38” | “47:53” | “68” | “99” | “36” |
| VK2735 2.5 mg (n=8) | “34” | “63:37” | “75” | “102” | “36” |
| VK2735 5 mg (n=7) | “29” | “43:57” | “71” | “97” | “34” |
| VK2735 10 mg (n=6) | “35” | “17:83” | “100” | “97” | “36” |
| VK2735 20 mg (n=8) | “35” | “63:37” | “88” | “111” | “36” |
| VK2735 40 mg (n=8) | “33” | “25:75” | “63” | “89” | “33” |
| VK2735 60 mg (n=9) | “44” | “33:67” | “89” | “108” | “37” |
| VK2735 80 mg (n=9) | “44” | “56:44” | “100” | “102” | “35” |
| VK2735 100 mg (n=9) | “44” | “44:56” | “67” | “103” | “35” |
Efficacy results
Oral formulation: weight loss at day 28 through 100 mg
Oral formulation: change in body weight by cohort at day 28
| Measure | Placebo (n=18) | 2.5 mg (n=8) | 5 mg (n=6) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=7) | 60 mg (n=9) | 80 mg (n=9) | 100 mg (n=9) |
|---|---|---|---|---|---|---|---|---|---|
| Mean baseline body weight | “98.3 kg” | “102.3 kg” | “95.3 kg” | “97.1 kg” | “111.3 kg” | “90.0 kg” | “107.7 kg” | “102.0 kg” | “102.7 kg” |
| Mean change from baseline body weight | “-1.4 kg” | “-0.3 kg” | “-0.8 kg” | “-1.3 kg” | “-3.6 kg” | “-4.8 kg” | “-4.4 kg” | “-5.3 kg” | “-8.2 kg” |
| Mean percent change from baseline | “-1.4 %” | “-0.3 %” | “-0.8 %” | “-1.1 %” | “-3.5 %” | “-5.1 %” | “-4.1 %” | “-5.2 %” | “-8.2 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “1.0 %” | “0.6 %” | “0.3 %” | “-2.2 %” | “-3.7 %” | “-2.7 %” | “-3.9 %” | “-6.8 %” |
| p-value vs. placebo | “-” | “-” | “-” | “-” | “0.0174” | “0.0001” | “0.0026” | “<0.0001” | “<0.0001” |
| Percent reporting at least 5% weight loss | “0 %” | “0 %” | “0 %” | “0 %” | “25 %” | “57 %” | “38 %” | “63 %” | “100 %” |
| p-value vs. placebo for at least 5% weight loss | “-” | “-” | “-” | “-” | “0.0933” | “0.0033” | “0.0243” | “0.0011” | “<0.0001” |
Oral formulation: daily to every-other-day transition at 80 mg
Oral formulation: progressive weight loss and durability through day 57
Oral formulation: pharmacokinetic exposure across doses
Oral formulation: satiety and decreased appetite
Oral formulation: summary in the corporate presentation
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Oral formulation: adverse event summary by cohort
| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) |
|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent adverse events | “16 (84%)” | “6 (75%)” | “6 (86%)” | “4 (67%)” | “6 (75%)” | “7 (88%)” | “9 (100%)” | “9 (100%)” | “8 (89%)” | “9 (100%)” |
| Drug-related treatment-emergent adverse events | “11 (58%)” | “4 (50%)” | “4 (57%)” | “3 (50%)” | “4 (50%)” | “7 (88%)” | “6 (67%)” | “9 (100%)” | “7 (78%)” | “9 (100%)” |
| Serious adverse events | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” | “1 (11%)” | “0 (0%)” | “0 (0%)” | “0 (0%)” |
Oral formulation: gastrointestinal adverse events by cohort
| Event | Placebo (n=19) | 2.5 mg (n=8) | 5 mg (n=7) | 10 mg (n=6) | 20 mg (n=8) | 40 mg (n=8) | 60 mg (n=9) | 80 mg A (n=9) | 80 mg B (n=9) | 100 mg (n=9) | Combined (n=73) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nausea, mild | “2 (11%)” | “0 (0%)” | “1 (14%)” | “0 (0%)” | “2 (25%)” | “2 (25%)” | “2 (22%)” | “6 (67%)” | “4 (44%)” | “6 (67%)” | “23 (32%)” |
| Vomiting | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “3 (4 %)” |
| Diarrhea | “4 (21 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (13 %)” | “0 (0 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “1 (11 %)” | “5 (7 %)” |
| Constipation | “3 (16 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “3 (33 %)” | “2 (22 %)” | “1 (11 %)” | “4 (44 %)” | “10 (14 %)” |
Oral formulation: severity of adverse events through 100 mg
Oral formulation: interim safety through 40 mg
Study limitations
Summary: study limitations
VK2735-101 Part C was the first administration of the oral tablet formulation, in otherwise healthy adults with a body mass index of at least 30 kg/m2 who took VK2735 once daily for 28 days with follow-up to day 57. Safety and tolerability were the primary objectives, and body weight was an exploratory measure. Each VK2735 cohort had 6 to 9 participants and the pooled placebo group had 17 to 19, depending on the analysis; the every-other-day cohort at 80 mg had 9 participants. The tablet doses studied (2.5 to 100 mg) differ from the doses carried into phase 3 (27.5, 35, and 55 mg), and 28 days of dosing does not show where weight loss plateaus. Part C has no registry record of its own: the ClinicalTrials.gov record for NCT05203237 describes Part C in its detailed description but registers a single primary outcome, safety after single subcutaneous doses over 8 days, and reports an actual enrollment of 92 for Parts A, B, and C, the same number the poster reports as randomized in Part C alone. The interim release of March 2024 stated that “no serious adverse events (SAEs) have been reported to date” for cohorts through 40 mg; the poster reports one serious adverse event in the 60 mg cohort (1 of 9, 11%) without describing it. Results are available only in press releases, a corporate presentation, and a congress poster, with no peer-reviewed publication and no results posted to the registry.